Literature DB >> 26343295

The long-lasting antidepressant effects of rapastinel (GLYX-13) are associated with a metaplasticity process in the medial prefrontal cortex and hippocampus.

J Burgdorf1, X-L Zhang2, C Weiss3, A Gross4, S R Boikess5, R A Kroes4, M A Khan4, R M Burch4, C S Rex5, J F Disterhoft3, P K Stanton2, J R Moskal6.   

Abstract

Rapastinel (GLYX-13) is an N-methyl-d-aspartate receptor (NMDAR) modulator that has characteristics of a glycine site partial agonist. Rapastinel is a robust cognitive enhancer and facilitates hippocampal long-term potentiation (LTP) of synaptic transmission in slices. In human clinical trials, rapastinel has been shown to produce marked antidepressant properties that last for at least one week following a single dose. The long-lasting antidepressant effect of a single dose of rapastinel (3mg/kg IV) was assessed in rats using the Porsolt, open field and ultrasonic vocalization assays. Cognitive enhancement was examined using the Morris water maze, positive emotional learning, and contextual fear extinction tests. LTP was assessed in hippocampal slices. Dendritic spine morphology was measured in the dentate gyrus and the medial prefrontal cortex. Significant antidepressant-like or cognitive enhancing effects were observed that lasted for at least one week in each model. Rapastinel facilitated LTP 1day-2weeks but not 4weeks post-dosing. Biweekly dosing with rapastinel sustained this effect for at least 8weeks. A single dose of rapastinel increased the proportion of whole-cell NMDAR current contributed by NR2B-containing NMDARs in the hippocampus 1week post-dosing, that returned to baseline by 4weeks post-dosing. The NMDAR antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) blocked the antidepressant-like effect of rapastinel 1week post dosing. A single injection of rapastinel also increased mature spine density in both brain regions 24h post-dosing. These data demonstrate that rapastinel produces its long-lasting antidepressant effects via triggering NMDAR-dependent processes that lead to increased sensitivity to LTP that persist for up to two weeks. These data also suggest that these processes led to the alterations in dendritic spine morphologies associated with the maintenance of long-term changes in synaptic plasticity associated with learning and memory.
Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GLYX-13; LTP; NMDA receptor; depression; hippocampus; medial prefrontal cortex

Mesh:

Substances:

Year:  2015        PMID: 26343295      PMCID: PMC4721228          DOI: 10.1016/j.neuroscience.2015.09.004

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  44 in total

1.  A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder.

Authors:  Lobna Ibrahim; Nancy Diaz Granados; Libby Jolkovsky; Nancy Brutsche; David A Luckenbaugh; W Joseph Herring; William Z Potter; Carlos A Zarate
Journal:  J Clin Psychopharmacol       Date:  2012-08       Impact factor: 3.153

2.  High-throughput, detailed, cell-specific neuroanatomy of dendritic spines using microinjection and confocal microscopy.

Authors:  Dani Dumitriu; Alfredo Rodriguez; John H Morrison
Journal:  Nat Protoc       Date:  2011-08-25       Impact factor: 13.491

Review 3.  Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of (1)H-MRS findings.

Authors:  J J Luykx; K G Laban; M P van den Heuvel; M P M Boks; R C W Mandl; R S Kahn; S C Bakker
Journal:  Neurosci Biobehav Rev       Date:  2011-06-06       Impact factor: 8.989

4.  Positive emotional learning is regulated in the medial prefrontal cortex by GluN2B-containing NMDA receptors.

Authors:  J Burgdorf; R A Kroes; C Weiss; M M Oh; J F Disterhoft; S M Brudzynski; J Panksepp; J R Moskal
Journal:  Neuroscience       Date:  2011-06-07       Impact factor: 3.590

Review 5.  Structural plasticity of dendritic spines.

Authors:  Miquel Bosch; Yasunori Hayashi
Journal:  Curr Opin Neurobiol       Date:  2011-09-28       Impact factor: 6.627

6.  GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator.

Authors:  Joseph R Moskal; Amy G Kuo; Craig Weiss; Paul L Wood; Amy O'Connor Hanson; Stephen Kelso; Robert B Harris; John F Disterhoft
Journal:  Neuropharmacology       Date:  2005-07-26       Impact factor: 5.250

Review 7.  Frequency-modulated 50 kHz ultrasonic vocalizations: a tool for uncovering the molecular substrates of positive affect.

Authors:  Jeffrey Burgdorf; Jaak Panksepp; Joseph R Moskal
Journal:  Neurosci Biobehav Rev       Date:  2010-12-07       Impact factor: 8.989

8.  Stress and amygdala suppression of metaplasticity in the medial prefrontal cortex.

Authors:  Gal Richter-Levin; Mouna Maroun
Journal:  Cereb Cortex       Date:  2010-01-15       Impact factor: 5.357

9.  NMDA GluN2B receptors involved in the antidepressant effects of curcumin in the forced swim test.

Authors:  Lin Zhang; Tianyuan Xu; Shuang Wang; Lanqing Yu; Dexiang Liu; Renzhi Zhan; Shu Yan Yu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-08-31       Impact factor: 5.067

10.  GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Authors:  Jeffrey Burgdorf; Xiao-lei Zhang; Katherine L Nicholson; Robert L Balster; J David Leander; Patric K Stanton; Amanda L Gross; Roger A Kroes; Joseph R Moskal
Journal:  Neuropsychopharmacology       Date:  2012-12-05       Impact factor: 7.853

View more
  28 in total

1.  GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine.

Authors:  Rong-Jian Liu; Catharine Duman; Taro Kato; Brendan Hare; Dora Lopresto; Eunyoung Bang; Jeffery Burgdorf; Joseph Moskal; Jane Taylor; George Aghajanian; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2016-09-16       Impact factor: 7.853

2.  Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.

Authors:  Ashley E Lepack; Eunyoung Bang; Boyoung Lee; Jason M Dwyer; Ronald S Duman
Journal:  Neuropharmacology       Date:  2016-09-12       Impact factor: 5.250

Review 3.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

Review 4.  Dendritic structural plasticity and neuropsychiatric disease.

Authors:  Marc P Forrest; Euan Parnell; Peter Penzes
Journal:  Nat Rev Neurosci       Date:  2018-03-16       Impact factor: 34.870

Review 5.  Mechanisms of ketamine action as an antidepressant.

Authors:  P Zanos; T D Gould
Journal:  Mol Psychiatry       Date:  2018-03-13       Impact factor: 15.992

6.  Contribution of skeletal muscular glycine to rapid antidepressant effects of ketamine in an inflammation-induced mouse model of depression.

Authors:  Niannian Huang; Yue Wang; Gaofeng Zhan; Fan Yu; Shan Li; Dongyu Hua; Riyue Jiang; Shiyong Li; Yeshun Wu; Ling Yang; Bin Zhu; Fei Hua; Ailin Luo; Chun Yang
Journal:  Psychopharmacology (Berl)       Date:  2019-07-18       Impact factor: 4.530

7.  Neuronal Nsun2 deficiency produces tRNA epitranscriptomic alterations and proteomic shifts impacting synaptic signaling and behavior.

Authors:  J Blaze; A Navickas; H L Phillips; S Heissel; A Plaza-Jennings; S Miglani; H Asgharian; M Foo; C D Katanski; C P Watkins; Z T Pennington; B Javidfar; S Espeso-Gil; B Rostandy; H Alwaseem; C G Hahn; H Molina; D J Cai; T Pan; W D Yao; H Goodarzi; F Haghighi; S Akbarian
Journal:  Nat Commun       Date:  2021-08-13       Impact factor: 17.694

8.  Investigational Drugs for the Treatment of Depression (Part 2): Glutamatergic, Cholinergic, Sestrin Modulators, and Other Agents.

Authors:  Octavian Vasiliu
Journal:  Front Pharmacol       Date:  2022-06-17       Impact factor: 5.988

Review 9.  Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Authors:  Todd D Gould; Carlos A Zarate; Scott M Thompson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-10-08       Impact factor: 13.820

Review 10.  Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants.

Authors:  Ronald S Duman; Satoshi Deyama; Manoela Viar Fogaça
Journal:  Eur J Neurosci       Date:  2019-12-20       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.